INTRODUCTION {#s1}
============

Kidney cancer accounting for 2% of all malignancies, it has become one of the most important health problems worldwide, cases are increasing year by year \[[@R1]\]. Renal cell carcinoma (RCC) is the major cancer type in kidney, and accounts for about 3% of all human malignancies, with a male-to-female ratio of approximately 2:1 \[[@R1], [@R2]\]. RCC risk factors included smoking tobacco \[[@R3]\], obesity \[[@R4], [@R5]\], hypertension \[[@R6]\], and a history of chronic kidney disease \[[@R7]\]. Besides the environmental risk factors, inherited risk has been considered crucial risk factors of RCC. A recent study has demonstrated that genetic factors contribute greatly to the occurrence of RCC. \[[@R8], [@R9]\]. Genome-wide association studies (GWAS) have shown EPAS1, HIF-2α, CCND1, ITPR2 were significantly associated with RCC susceptibility in western populations \[[@R10]--[@R13]\]. However, these GWAS identified RCC risk SNPs identified in western populations was rarely replicated in Chinese populations. The potential role of RCC risk in immune response has been demonstrated \[[@R14], [@R15]\]. RCC tissue is often infiltrated by lymphocytes, macrophages and dendritic cells, reflecting the immunogenicity of RCC \[[@R16]--[@R18]\]. The present pathogenic mechanism of RCC, because of these two inflammatory conditions, is characterized by the presence of a wide range of proinflammatory cytokines. It has also been shown a variety of cytokines such as tumor necrosis factor alpha (TNF- alpha), interleukin -6 (IL-6), type 1 interferons (IFNs) and interferon gamma *in vitro* \[[@R19]--[@R22]\]. The effects of cytokines observed in these studies were either growth promoting or antiproliferative \[[@R21]\]. In addition, polymorphisms in the immune response may explain human diversity because they lead to differences in the ability of individuals to produce cytokines, resulting in a wide variety of biological consequences. Although many studies investigating the frequency of cytokine gene polymorphisms appear in chronic kidney disease patients, there is still a lack of IL1 regarding how renal cancer can be related. Therefore, the purpose of this study was to investigate the IL-1 cytokine gene polymorphism and cytokine receptor gene polymorphism in RCC patients.

RESULTS {#s2}
=======

Demographic and clinical features of the RCC and the control group are shown in Table [1](#T1){ref-type="table"}. The cases were well matched with the controls in terms of age (P = 0.273) and gender (P = 0.017), smoking status (P = 0.193). However, drinking status exist significant difference between two groups (P\< 0.05). In Table [2](#T2){ref-type="table"}, we listed the primers in the study. All SNPs were in Hardy--Weinberg equilibrium among control subjects, in addition to rs928940. The distributions of the allele frequencies for all selected polymorphisms are presented in Table [3](#T3){ref-type="table"}. Our results indicated that polymorphism rs3783550, rs3783546, rs1609682 and rs3783521 in IL1A gene are associated with susceptibility to RCC. We hypothesized that harboring minor allele per SNP is a risk factor, compared with owning wild-type alleles. The results of various genetic models are shown in Table [4](#T4){ref-type="table"}. Five SNPs were significantly associated with RCC risk in Chinese han population, and were used to establish the genetic risk models. Our results showed that the rs3783550 T allele carriers (dominant, Log-additive model) was associated with an increased risk of RCC (dominant, OR=1.39, 95%CI = 1.03-1.88, P= 0.031; Log-additive, OR=1.32, 95%CI = 1.05-1.64, P= 0.015). The genotype "C/C" and "G/C-C/C" of rs3783546 in IL1A gene was associated with of RCC risk in Codominant(OR = 1.77, 95% CI=1.09-2.87, p = 0.04), dominant model (OR=1.41, 95%CI = 1.04-1.91, P= 0.025). For rs1609682, carriers "T" allel individual, increased RCC risk (OR=1.32, 95%CI = 1.06-1.65, P= 0.013). The genotype "G/G" and "G/A-G/G" of rs3783521 was associated with an increased risk of RCC in Codominant, dominant, and Log-additive model (OR = 1.33, 95% CI= 1.06-1.66, p = 0.012). Meanwhile, we adjustment for age, sex, we found rs1143623(G) were associated with RCC risk in recessive model(OR = 1.54, 95% CI= 1.02-2.32, p = 0.04).

###### Characteristics of RCC patients and control participants

  Variable          Case          Control       P
  ----------------- ------------- ------------- ---------
  Total             291           463           
  Age(Mean±SD)      56.88±11.66   50.65±11.79   0.273
  BMI(Mean±SD)      23.96±2.90    23.79±3.77    0.098
  Gender                                        
   Female           99            198           0.017
   Male             192           265           
  Smoking status                                
   Smoking          120           169           0.193
   Nosmoking        171           294           
  Drinking status                               
   Drinking         53            174           \<0.050
   Nodrinking       238           289           

###### PCR primers

  SNP          1st-PCR primer sequences         2st-PCR primer sequences         UEP sequences
  ------------ -------------------------------- -------------------------------- ----------------------------
  rs3783550    ACGTTGGATGTGAAGGCCAAATGCTAAGGG   ACGTTGGATGCTCAGGCATCTCCTATGAAG   cGAATTCTGTTAGAGAACAAGATG
  rs3783546    ACGTTGGATGACACTGCTGTTGGCACTATG   ACGTTGGATGGTAGGGCAGTAGCTTCATTC   ccTTATTCACTGAGAGCCTT
  rs2856838    ACGTTGGATGCTGGTGTCAGAGAAGACAAC   ACGTTGGATGGTTAGTTATGCCATCCTGAG   CCAGGTGTCTGTCTCCTAA
  rs1609682    ACGTTGGATGCATGGGACTGCTATTCTTAC   ACGTTGGATGACCTCTAGTGAGGGTAAAAC   gAGTGAGGGTAAAACAAAAGTATT
  rs3783521    ACGTTGGATGCCAACTGGCTACATTTCTGC   ACGTTGGATGTCAGGAGGAGAGGGTTAATC   ccTGTTGCCTAAAGAGGAA
  rs2853550    ACGTTGGATGCGAAGACTATCCTCCTCACC   ACGTTGGATGTGCAGTGCTTCAGCTGATCC   CAGCTGATCCTGTTCCA
  rs1143643    ACGTTGGATGCCTCAGCATTTGGCACTAAG   ACGTTGGATGACTCCTGAGTTGTAACTGGG   GGGCCCCCAACTTTC
  rs3136558    ACGTTGGATGAAGGGCTTGAAAGAATCCCG   ACGTTGGATGGATTCATCCACCTCGGCTTC   aaccCGCCTGGCCCAGAGAGGGATGA
  rs1143630    ACGTTGGATGTCTTGAGTCTGCCTCTAACC   ACGTTGGATGAGATTATCCCTCTCTGAAGC   AGCTCAAGGAGGTTAAG
  rs1143627    ACGTTGGATGTCTCAGCCTCCTACTTCTGC   ACGTTGGATGTTGTGCCTCGAAGAGGTTTG   gtTCCCTCGCTGTTTTTAT
  rs16944      ACGTTGGATGCTGTCTGTATTGAGGGTGTG   ACGTTGGATGAGAGGCTCCTGCAATTGACA   AATTGACAGAGAGCTCC
  rs1143623    ACGTTGGATGACCTATTTCCCTCGTGTCTC   ACGTTGGATGATGTGCCAGGTATCGTGCTC   tttaGTGCTCGCTCTGCATTAT
  rs17042888   ACGTTGGATGTGGAGTTGGAGTCTTGTTGG   ACGTTGGATGCTACTTGCTCAGCACCATAC   agcGGTGTTGAAATCCCAAAA
  rs928940     ACGTTGGATGACATGGTTCCATCTCTATCC   ACGTTGGATGAGAAGAGAAAAGTTGACGGG   aTGACGGGGTGCATACTC
  rs3181052    ACGTTGGATGCTTTATGTTTGTCTGGGCCG   ACGTTGGATGACAGTCCCCATATCTGGAAG   cttaACTCATACACCCACAGAGCC
  rs452204     ACGTTGGATGAAAAGAGCCTCAACATGCAG   ACGTTGGATGTAGACTTAGCCACGTGACTG   gcccATAGGATGATGCAAGCAGAAGT

###### Basic information of candidate SNPs in this study

  SNP          Chr    Gene    allel   MAF(case)   MAF(control)   HWE     OR     95%CI   P      
  ------------ ------ ------- ------- ----------- -------------- ------- ------ ------- ------ ---------
  rs3783550    2q13   IL1A    T/G     0.38        0.33           0.399   1.28   1.04    1.58   0.018\*
  rs3783546    2q13   IL1A    C/G     0.38        0.33           0.459   1.30   1.05    1.60   0.014\*
  rs2856838    2q13   IL1A    A/G     0.27        0.25           0.320   1.12   0.89    1.40   0.338
  rs1609682    2q13   IL1A    T/G     0.38        0.33           0.398   1.29   1.05    1.59   0.016\*
  rs3783521    2q13   IL1A    G/A     0.38        0.33           0.399   1.29   1.05    1.59   0.015\*
  rs2853550    2q13   IL1B    A/G     0.11        0.09           0.067   1.29   0.92    1.79   0.137
  rs1143643    2q13   IL1B    C/T     0.48        0.47           0.191   1.01   0.83    1.23   0.926
  rs3136558    2q13   IL1B    G/A     0.41        0.37           0.617   1.21   0.99    1.48   0.066
  rs1143630    2q13   IL1B    T/G     0.18        0.16           1.000   1.16   0.89    1.51   0.262
  rs1143627    2q13   IL1B    G/A     0.49        0.48           0.160   1.05   0.86    1.28   0.618
  rs16944      2q13   IL1B    A/G     0.49        0.48           0.162   1.06   0.87    1.29   0.556
  rs1143623    2q13   IL1B    G/C     0.41        0.40           0.286   1.04   0.85    1.28   0.675
  rs17042888   2q13   IL1RN   A/G     0.27        0.26           0.470   1.05   0.84    1.31   0.697
  rs928940     2q13   IL1RN   T/G     0.41        0.39           0.000   1.07   0.87    1.31   0.510
  rs3181052    2q13   IL1RN   G/A     0.43        0.41           0.248   1.09   0.89    1.34   0.384
  rs452204     2q13   IL1RN   G/A     0.36        0.35           1.000   1.06   0.86    1.30   0.594

\**p* value ≤ 0.05 indicates statistical significance; *A/B* stands for minor/major alleles on the control sample frequencies. *HWE*: Hardy--Weinberg equilibrium*; MAF*: minor allele frequency; OR: odds ratio; SNP: single-nucleotide polymorphisms.

###### Association between IL1 polymorphisms genotypes and RCC risk under different genotypic models

                 Model         Genotype      control            case               OR (95% CI)   P-value
  -------------- ------------- ------------- ------------------ ------------------ ------------- ---------
  rs3783550      Codominant    G/G           206 (44.5%)        106 (36.5%)        1             
  G/T            212 (45.8%)   144 (49.7%)   1.32 (0.96-1.81)   0.053                            
  T/T            45 (9.7%)     40 (13.8%)    1.73 (1.06-2.81)                                    
  Dominant       G/G           206 (44.5%)   106 (36.5%)        1                  0.031\*       
  G/T-T/T        257 (55.5%)   184 (63.5%)   1.39 (1.03-1.88)                                    
  Recessive      G/G-G/T       418 (90.3%)   250 (86.2%)        1                  0.089         
  T/T            45 (9.7%)     40 (13.8%)    1.49 (0.94-2.34)                                    
  Log-additive   \-\--         \-\--         \-\--              1.32 (1.05-1.64)   0.015\*       
  rs3783546      Codominant    G/G           206 (44.7%)        106 (36.4%)        1             0.040\*
  G/C            210 (45.5%)   144 (49.5%)   1.33 (0.97-1.83)                                    
  C/C            45 (9.8%)     41 (14.1%)    1.77 (1.09-2.87)                                    
  Dominant       G/G           206 (44.7%)   106 (36.4%)        1                  0.025\*       
  G/C-C/C        255 (55.3%)   185 (63.6%)   1.41 (1.04-1.91)                                    
  Recessive      G/G-G/C       416 (90.2%)   250 (85.9%)        1                  0.072         
  C/C            45 (9.8%)     41 (14.1%)    1.52 (0.97-2.38)                                    
  Log-additive   \-\--         \-\--         \-\--              1.33 (1.07-1.66)   0.011\*       
  rs1609682      CoDominant    G/G           205 (44.4%)        106 (36.4%)        1             0.046\*
  G/T            212 (45.9%)   144 (49.5%)   1.31 (0.96-1.80)                                    
  T/T            45 (9.7%)     41 (14.1%)    1.76 (1.09-2.86)                                    
  Dominant       G/G           205 (44.4%)   106 (36.4%)        1                  0.031\*       
  G/T-T/T        257 (55.6%)   185 (63.6%)   1.39 (1.03-1.88)                                    
  Recessive      G/G-G/T       417 (90.3%)   250 (85.9%)        1                  0.070         
  T/T            45 (9.7%)     41 (14.1%)    1.52 (0.97-2.39)                                    
  Log-additive   \-\--         \-\--         \-\--              1.32 (1.06-1.65)   0.013\*       
  rs3783521      CoDominant    A/A           206 (44.5%)        106 (36.4%)        1             0.043\*
  G/A            212 (45.8%)   144 (49.5%)   1.32 (0.96-1.81)                                    
  G/G            45 (9.7%)     41 (14.1%)    1.77 (1.09-2.87)                                    
  Dominant       A/A           206 (44.5%)   106 (36.4%)        1                  0.028\*       
  G/A-G/G        257 (55.5%)   185 (63.6%)   1.40 (1.04-1.89)                                    
  Recessive      A/A-G/A       418 (90.3%)   250 (85.9%)        1                  0.069         
  G/G            45 (9.7%)     41 (14.1%)    1.52 (0.97-2.39)                                    
  Log-additive   \-\--         \-\--         \-\--              1.33 (1.06-1.66)   0.012\*       
  rs1143623      CoDominant    C/C           159 (34.6%)        110 (37.9%)        1             0.065
  C/G            233 (50.6%)   124 (42.8%)   0.82 (0.59-1.16)                                    
  G/G            68 (14.8%)    56 (19.3%)    1.38 (0.88-2.17)                                    
  Dominant       C/C           159 (34.6%)   110 (37.9%)        1                  0.720         
  C/G-G/G        301 (65.4%)   180 (62.1%)   0.94 (0.69-1.30)                                    
  Recessive      C/C-C/G       392 (85.2%)   234 (80.7%)        1                  0.040\*       
  G/G            68 (14.8%)    56 (19.3%)    1.54 (1.02-2.32)                                    
  Log-additive   \-\--         \-\--         \-\--              1.10 (0.88-1.37)   0.400         

The LD and haplotype analysis were investigated. We found one block in studied IL1A SNPs (Figure [1](#F1){ref-type="fig"}). In Table [5](#T5){ref-type="table"} we listed the association between IL1A haplotype and the risk of RCC. Haplotype estimation analysis showed that the haplotype of rs3783550T/ rs3783546C/ rs2856838G/ rs1609682T/rs3783521G(TCGTG) It could be a potential risk factor for RCC (OR = 1.68, 95% CI= 1.19 - 2.37, p = 0.0032).

![Haplotype block map for the IL1 SNPs genotyped in this study](oncotarget-08-56021-g001){#F1}

###### Haplotype frequencies and their associations with RCC risk

  Block   rs3783550   rs3783546   rs2856838   rs1609682   rs3783521   Freq     OR (95% CI)          P-value
  ------- ----------- ----------- ----------- ----------- ----------- -------- -------------------- ---------
  1       G           G           G           G           A           0.6499   1                    \-\--
  2       T           C           A           T           G           0.2555   1.20 (0.93 - 1.54)   0.160
  3       T           C           G           T           G           0.0946   1.68 (1.19 - 2.37)   0.003\*

In addition we also carried out smoking, drinking, age stratification analysis, we found in smoking population there have six SNPs rs3783550 (P=0.029), rs3783546 (P =0.019), rs1609682 (P=0.023), rs3783521 (P=0.021), rs1143630 (P=0.045), rs3136558 (P=0.020) polymorphism were associated with RCC, however, in nosmoking population we did not found any SNPs with RCC. Meanwhile, in nodrinking there was also a significant relationship between the risk of RCC of six SNPs except rs1143630 and rs3136558. For age \> 55, five SNPs polymorphism (rs3783550 (P=0.003), rs3783546 (P =0.003), rs2856838 (P=0.020), rs1609682 (P=0.003), rs3783521 (P=0.003) were associated with RCC risk (Table [6](#T6){ref-type="table"}).

###### The association between SNPs and smoking, drinking status, age analysis of RCC patients

  SNP          Allel   Smoking status    Drinking status   Age                                                                                                                       
  ------------ ------- ----------------- ----------------- ----------------- ------- ----------------- ------- ----------------- ------- ----------------- ------- ----------------- -------
  rs3783550    T/G     1.37(1.03-1.81)   0.029             1.20(0.85-1.68)   0.308   0.95(0.60-1.50)   0.823   1.43(1.11-1.85)   0.006   1.43(1.11-1.85)   0.003   1.01(0.74-1.38)   0.959
  rs3783546    C/G     1.39(1.05-1.84)   0.019             1.20(0.85-1.68)   0.308   0.95(0.60-1.51)   0.836   1.45(1.13-1.87)   0.004   1.45(1.13-1.87)   0.003   1.03(0.76-1.41)   0.831
  rs2856838    A/G     1.18(0.87-1.61)   0.284             0.99(0.68-1.43)   0.941   0.93(0.57-1.53)   0.774   0.83(0.63-1.10)   0.198   0.83(0.63-1.10)   0.020   0.81(0.57-1.14)   0.227
  rs1609682    T/G     1.38(1.04-1.82)   0.023             1.20(0.85-1.68)   0.308   0.95(0.60-1.50)   0.823   1.44(1.12-1.85)   0.005   1.44(1.12-1.85)   0.003   1.03(0.75-1.41)   0.845
  rs3783521    G/A     1.39(1.05-1.83)   0.021             1.20(0.85-1.68)   0.308   0.95(0.60-1.50)   0.823   1.45(1.12-1.86)   0.004   1.45(1.12-1.86)   0.003   1.03(0.75-1.41)   0.845
  rs2853550    A/G     1.43(0.93-2.21)   0.106             1.17(0.66-2.06)   0.591   0.80(0.36-1.80)   0.589   1.49(0.99-2.23)   0.052   1.49(0.99-2.23)   0.142   1.26(0.78-2.03)   0.340
  rs1143643    C/T     1.10(0.84-1.43)   0.495             1.30(0.93-1.82)   0.121   0.95(0.62-1.48)   0.836   1.01(0.79-1.29)   0.939   1.01(0.79-1.29)   0.453   0.98(0.73-1.31)   0.869
  rs3136558    G/A     1.38(1.05-1.82)   0.020             0.94(0.67-1.32)   0.708   1.11(0.71-1.74)   0.644   1.20(0.93-1.53)   0.157   1.20(0.93-1.53)   0.817   1.36(1.01-1.84)   0.044
  rs1143630    T/G     1.43(1.01-2.04)   0.045             0.82(0.53-1.28)   0.381   0.79(0.43-1.46)   0.453   0.77(0.56-1.07)   0.114   0.77(0.56-1.07)   0.162   1.06(0.72-1.56)   0.764
  rs1143627    G/A     1.03(0.78-1.34)   0.851             1.10(0.79-1.54)   0.568   0.95(0.61-1.47)   0.814   1.03(0.81-1.32)   0.803   1.03(0.81-1.32)   0.414   0.98(0.73-1.32)   0.915
  rs16944      A/G     1.03(0.79-1.35)   0.803             1.11(0.79-1.54)   0.548   0.96(0.62-1.48)   0.847   1.04(0.82-1.33)   0.738   1.04(0.82-1.33)   0.291   0.97(0.72-1.30)   0.834
  rs1143623    G/C     0.97(0.74-1.27)   0.801             1.16(0.83-1.64)   0.378   1.02(0.65-1.60)   0.933   1.01(0.79-1.29)   0.944   1.01(0.79-1.29)   0.592   1.01(0.75-1.36)   0.965
  rs17042888   A/G     0.82(0.60-1.11)   0.194             1.34(0.92-1.95)   0.129   0.89(0.53-1.49)   0.663   1.02(0.77-1.34)   0.915   1.02(0.77-1.34)   0.974   1.00(0.72-1.40)   0.996
  rs928940     T/G     0.89(0.68-1.18)   0.429             1.20(0.86-1.69)   0.287   0.95(0.61-1.49)   0.824   1.03(0.80-1.32)   0.831   1.03(0.80-1.32)   0.528   1.14(0.84-1.54)   0.406
  rs3181052    G/A     1.00(0.77-1.31)   0.983             1.13(0.80-1.57)   0.491   0.89(0.57-1.39)   0.620   1.10(0.86-1.41)   0.451   1.10(0.86-1.41)   0.226   1.33(0.99-1.79)   0.061
  rs452204     G/A     0.93(0.70-1.23)   0.605             1.22(0.86-1.72)   0.268   1.06(0.67-1.67)   0.811   1.02(0.79-1.32)   0.876   1.02(0.79-1.32)   0.398   1.25(0.92-1.70)   0.159

DISCUSSION {#s3}
==========

In our case-control study of RCC, we elaborated the associations of 16 SNPs in *IL1A, IL1B and IL1RN* with the risk of RCC in Chinese han population. Our study revealed that IL1A and IL1B SNPs were associated with susceptibility to RCC, but there was no significant association between SNP and the risk of RCC in IL1RN.

We selected locus 2q13 in IL1A, IL1B, IL1RN three candidate genes were analyzed. The proteins encoded by these genes belong to interleukin -1 (IL-1). The three molecules in the IL-1 cluster, namely, IL-1α, IL-1β, and interleukin-1 receptor antagonist (IL-1Ra), are encoded by the IL1A, IL1B, and IL1RN genes, respectively \[[@R23]--[@R25]\]. IL-1 cytokines are a major inflammatory cytokine and have been implicated in the mediation of acute and chronic inflammatory diseases. It is a key mediator of inflammation, with pleiotropic effects on several cells and signaling pathways. IL-1 is a pleiotropic cytokine that participates in stimulating immune responses, such as inflammation, and regulates cellular growth, differentiation, and movement of cells. It is secreted by viruses, bacteria, and fungi that react to various antigens \[[@R26]\]. IL-1 cytokines are known to contribute to the development and progression of a number of renal diseases \[[@R27], [@R28]\], and polymorphisms of the IL-1 family cytokine genes have been studied for associations with IgAN susceptibility, progression, and clinical manifestations, such as hematuria and proteinuria. Several associations have been reported between IL-1 cluster gene polymorphisms and IgAN. However, IL-1cluster gene polymorphisms did not reported in RCC. The IL gene reported more focused on asthma, liver cancer, breast cancer, oral cancer, cervical cancer, leukemia and other research, at about rs3783550, rs3783546, rs1609682, rs3783521 polymorphisms were renal cell carcinoma and the related reports.

Smoking has been regarded as one of the risk factors of RCC. The risk of RCC caused by polymorphism is particularly significant in the smoking population, which may be caused by cigarette smoking induced immune suppression, so that renal cell carcinoma escape immune surveillance, thereby promoting the occurrence and development of renal cell carcinoma \[[@R29]\]. Studies have reported that between alcohol consumption and risk of renal cell carcinoma has a dose-dependent relationship, namely alcohol consumption to achieve a certain degree of risk exists only a small amount of alcohol, but can play the role of is beneficial to the body \[[@R30]\], this can be a very good explanation to our other hierarchical analysis results, the relative risk of drinkers for non-drinkers carrying the variant genotype and higher risk of RCC. These risk factors and genetic factors interact to affect the susceptibility of renal cancer. However, due to the limitations of data collection, the study of environmental factors are limited to smoking, drinking and other factors, so it is not able to completely analyze the interaction of gene environment. Therefore, it is necessary to carry out a complete analysis of the gene environment interaction, and to verify the results of the study.

Our results need to be validated in a larger sample and in other races with functional analysis to clarify the potential mechanisms underlying the links between SNPs of IL-1 and susceptibility to RCC.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

The case-control study included 291 histopathologically confirmed RCC patients and 463 controls. None of the patients had a family history of carcinoma. A total of 291 patients with RCC were prospectively recruited from People\'s Hospital of Hainan Province, Haikou people\'s Hospital Affiliated to Xiangya Medical School of Central South University, and First Affiliated Hospital of Sun Yat-sen University, and 463 healthy controls from the same region were enrolled in this study. Detailed characteristics of the RCC patients and controls are shown in Table [1](#T1){ref-type="table"}. The control group had no history of other tumors and was unrelated to the genes in RCC patients. General examinations, laboratory tests, and medical histories confirmed their health. Everyone personally asked the trained interviewer to collect information about demographic data and related factors using a pre-test questionnaire (smoking, drinking, BMI et al). This study was approved by People\'s Hospital of Hainan Province, Haikou people\'s Hospital Affiliated to Xiangya Medical School of Central South University, and First Affiliated Hospital of Sun Yat-sen University, and all individuals involved in this study have signed informed consent. After informed consent was issued by all individuals, 5-ml samples of venous blood were collected for genomic DNA extraction.

Selection of single nucleotide polymorphisms and genotyping {#s4_2}
-----------------------------------------------------------

Candidate SNPs were selected according to the following restrictions: (1) The SNPs located at IL1; (2) each SNP had minor allele frequency (MAF) of \> 5% in Chinese Han population; (3) each SNP had an r^2^ of \> 0.80. Thus, for this study, we have selected the 16 SNPs described (Table [2](#T2){ref-type="table"}). Whole blood were extracted using GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd. Xi'an City, China). We measured DNA concentration using NanoDrop 2000 spectrophotometer. Sequenom MassARRAY Assay Design 3.0 Software was used to design a Multiplexed SNP MassEXTEND assay \[[@R31]\]. Sequenom MassARRAY RS1000 was used for genotyping, and the related data were managed using Sequenom Typer 4.0 Software \[[@R31], [@R32]\].

Laboratory personnel were blinded to the genotyping results of all samples.

Statistical analysis {#s4_3}
--------------------

All SNPs performed Hardy Weinberg balance (HWE) performed by comparing the observed and expected frequencies of genotypes using χ^2^ analysis \[[@R33]\]. OR and 95%CI were calculated using the logistic regression model. The association between SNPs and RCC risk were analyzed by logistic regression (Four genetic models dominant, recessive, and additive model). The haplotype frequencies were determined using the SHEsis program.

Finally, we used statistical packages (4.2 Edition) to perform linkage disequilibrium (LD), haplotype genetic association construction, and polymorphism at loci \[[@R34], [@R35]\]. All p values were two-sided, and p \<0.05 was indicated statistical significance.
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